Need – 280M of people worldwide suffer from major depressive disorders (MDD). Although there is a well populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who fully benefit from the current therapeutic journey.
OPADE’s objective is to identify key biomarkers that support the decision-making process of the healthcare providers through the development and commercialisation of an AI (artificial intelligence) / ML (machine learning) -predictive tool.
The project focuses on the gut–brain-axis which plays a major role in MDD. Through clinical
investigations, the consortium partners will study the combination between genetics, epigenetics,
microbiome and inflammatory networks to:
Cluj-Napoca | Str. Alexandru Vlahuta, LAMA C/45 | Romania, CJ 400310